



**Universiteit
Leiden**
The Netherlands

Sex differences in onset to hospital arrival time, prestroke disability, and clinical symptoms in patients with a large vessel occlusion: a MR CLEAN Registry substudy

Ali, M.; Meij, A. van der; Os, H.J.A. van; Zwet, E.W. van; Spaander, F.H.M.; Hofmeijer, J.; ...
; MR CLEAN Registry Investigators

Citation

Ali, M., Meij, A. van der, Os, H. J. A. van, Zwet, E. W. van, Spaander, F. H. M., Hofmeijer, J., ... Wermer, M. J. H. (2022). Sex differences in onset to hospital arrival time, prestroke disability, and clinical symptoms in patients with a large vessel occlusion: a MR CLEAN Registry substudy. *Journal Of Neurointerventional Surgery*. doi:10.1136/jnis-2022-019670

Version: Publisher's Version




License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3502241>

Note: To cite this publication please use the final published version (if applicable).

Original research

Sex differences in onset to hospital arrival time, prestroke disability, and clinical symptoms in patients with a large vessel occlusion: a MR CLEAN Registry substudy

Mariam Ali ¹, Anne van der Meij,² Hendrikus J A van Os,² Mahsoem Ali ³, Erik W Van Zwet,⁴ Fianne H M Spaander,⁵ Jeanette Hofmeijer,^{6,7} Paul J Nederkoorn,⁸ Ido R van den Wijngaard,^{2,9} Charles B L M Majoie ¹⁰, Adriaan C G M van Es,¹¹ Wouter J Schonewille ¹², Marianne A A van Walderveen,¹³ Diederik W J Dippel ¹⁴, Marieke C Visser,¹ Nyika D Kruij,² Marieke J H Wermer,² on behalf of the MR CLEAN Registry Investigators

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnis-2022-019670>).

For numbered affiliations see end of article.

Correspondence to

Mariam Ali, Neurology, Amsterdam UMC Locatie VUmc, 1081 HV Amsterdam, Netherlands; m.ali2@amsterdamumc.nl

Received 21 September 2022
Accepted 27 October 2022
Published Online First
15 November 2022

ABSTRACT

Background Women have been reported to have worse outcomes after endovascular treatment (EVT), despite a similar treatment effect in non-clinical trial populations. We aimed to assess sex differences at hospital presentation with respect to workflow metrics, prestroke disability, and presenting clinical symptoms.

Methods We included consecutive patients from the Multicentre Randomised Controlled Trial of Endovascular Treatment for Acute Ischaemic Stroke in The Netherlands (MR CLEAN) Registry (2014–2018) who received EVT for anterior circulation large vessel occlusion (LVO). We assessed sex differences in workflow metrics, prestroke disability (modified Rankin Scale (mRS) score ≥ 1), and stroke severity and symptoms according to the National Institutes of Health Stroke Scale (NIHSS) score on hospital admission with logistic and linear regression analyses and calculated the adjusted OR (aOR).

Results We included 4872 patients (47.6% women). Compared with men, women were older (median age 76 vs 70 years) and less often achieved good functional outcome at 90 days (mRS ≤ 2 : 35.2% vs 46.4%, aOR 0.70, 95% CI 0.60 to 0.82). Mean onset-to-door time was longer in women (2 hours 16 min vs 2 hours 7 min, adjusted delay 9 min, 95% CI 4 to 13). This delay contributed to longer onset-to-groin times (3 hours 26 min in women vs 3 hours 13 min in men, adjusted delay 13 min, 95% CI 9 to 17). Women more often had prestroke disability (mRS ≥ 1 : 41.1% vs 29.1%, aOR 1.57, 95% CI 1.36 to 1.82). NIHSS on admission was essentially similar in men and women (mean 15 ± 6 vs 15 ± 6 , NIHSS < 10 vs ≥ 10 , aOR 0.91, 95% CI 0.78 to 1.06). There were no clear sex differences in the occurrence of specific stroke symptoms.

Conclusion Women with LVO had longer onset-to-door times and more often prestroke disability than men. Raising awareness of these differences at hospital presentation and investigating underlying causes may help to improve outcome after EVT in women.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Several studies have reported worse outcomes after endovascular thrombectomy for anterior circulation large vessel occlusion in women compared with men, but the underlying cause of this possible difference remains unclear.

WHAT THIS STUDY ADDS

⇒ In this large real world population with observational data from the Multicentre Randomised Controlled Trial of Endovascular Treatment for Acute Ischaemic Stroke in The Netherlands (MR CLEAN) Registry, we confirmed the poor outcomes in women, and found that women more often had prestroke disability and longer onset-to-door-times compared with men. These sex differences may partly explain the poor outcomes.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY

⇒ More detailed studies of specific processes of prehospital workflow are necessary to understand the origin of the sex disparity in hospital arrival times. With further data it may become possible to create specific stroke awareness campaigns targeted towards women to reduce patient delay in seeking treatment.

INTRODUCTION

Several observational studies have reported worse outcomes following endovascular treatment (EVT) for acute ischemic stroke due to large vessel occlusion (LVO) in women compared with men, despite a similar treatment effect according to most randomized controlled trials.^{1–7} The underlying cause of this possible difference remains poorly understood. After stroke, in general, there are indications that a poorer outcome in women is related to worse prestroke disability.⁸ Characteristics that are more common in women at the onset of stroke, such as



© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Ali M, van der Meij A, van Os HJA, et al. *J NeuroIntervent Surg* 2023;**15**:e255–e261.

Table 1 Baseline characteristics of participants stratified by sex

	All patients (n=4872)	Women (n=2320)	Men (n=2552)	P value
Age (years) (median (IQR))	72 (62–81)	76 (65–83)	70 (61–78)	<0.001
Systolic blood pressure (mm Hg) (mean (SD))*	150 (26)	151 (26)	149 (25)	0.02
Diastolic blood pressure (mm Hg) (mean (SD))†	83 (16)	82 (17)	84 (15)	<0.001
Vascular risk factors (n/total No (%))				
Hypertension	2542/4779 (53.2)	1333/2278 (58.5)	1209/2501 (48.3)	<0.001
Hypercholesterolemia	1463/4673 (31.3)	690/2214 (31.2)	773/2459 (31.4)	0.84
Diabetes mellitus	820/4842 (16.9)	415/2304 (18.0)	405/2538 (16.0)	0.06
Current smoker	995/3645 (27.3)	411/1737 (23.7)	584/1908 (30.6)	<0.001
Atrial fibrillation	1162/4807 (24.2)	590/2290 (25.8)	572/2517 (22.7)	0.01
Vascular comorbidities (n/total No (%))				
Ischemic stroke	866/4833 (17.9)	431/2301 (18.7)	435/2532 (17.2)	0.16
Intracerebral hemorrhage	89/4511 (2.0)	47/2147 (2.1)	42/2364 (1.8)	0.60
Myocardial infarction	696/4781 (14.6)	251/2282 (11.0)	445/2499 (17.8)	<0.001
Peripheral arterial disease	439/4781 (9.2)	190/2278 (8.3)	249/2503 (9.9)	0.06
Medication use (n/total No (%))				
DOAC	233/4815 (4.8)	107/2296 (4.7)	126/2519 (5.0)	0.58
Coumarin	613/4831 (12.7)	320/2303 (13.9)	293/2528 (11.6)	0.02
Antiplatelets	1516/4810 (31.5)	686/2289 (30.0)	830/2521 (32.9)	0.03
Antihypertensive agent	2652/4775 (55.5)	1366/2279 (59.9)	1286/2496 (51.5)	<0.001
Statin	1726/4767 (36.2)	790/2275 (34.7)	936/2492 (37.6)	0.04
TOAST classification (n/total No (%))‡				
Large artery atherosclerosis	185/1393 (13.3)	61/646 (9.4)	124/747 (16.6)	<0.001
Cardioembolic	465/1393 (33.4)	245/646 (37.9)	220/747 (29.5)	<0.001
Small vessel occlusion	0	0	0	1.00
Other cause	120/1393 (8.6)	47/646 (7.3)	73/747 (9.8)	0.10
Undetermined cause	678/1393 (48.7)	312/646 (48.3)	366/747 (49.0)	0.79

*Number of missing values: 143 (2.9%), 74 (3.2%), and 69 (2.7%) in all patients, women, and men, respectively.
†Number of missing values: 167 (3.4%), 92 (4.0%), and 75 (2.9%) in all patients, women, and men, respectively.
‡Data were available for only 1393 participants from part I of the Multicentre Randomised Controlled Trial of Endovascular Treatment for Acute Ischaemic Stroke in The Netherlands (MR CLEAN) Registry.
DOAC, direct oral anticoagulants; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke Treatment.

advanced age and higher comorbidity burden, increase the likelihood of prestroke disability.⁹ In addition, women are at risk for late arrival because they are more likely to live alone and less likely to call an ambulance for themselves.^{10 11} Differences in clinical presentation of LVO could also contribute to these delays and may lead to underdiagnosis and undertreatment of women.¹² In a recent meta-analysis on sex differences in clinical presentation of ischemic stroke, we found that women more frequently presented with non-focal stroke symptoms, such as mental status changes, loss of consciousness, and headache, than men (pooled OR 1.20, 95% CI 1.04 to 1.38).¹³ However, the possibility of misdiagnosis of LVO stroke seems to be low because neurological deficits are typically severe, but potential differences in clinical presentation of LVO stroke remain important because, for example, non-focal symptoms may lead to a delay in recognition.

We aimed to assess sex differences at hospital presentation with respect to (1) workflow metrics, (2) prestroke disability, and (3) clinical symptoms of patients with anterior circulation LVO to improve our understanding of the difference in outcome after EVT between men and women in the real world setting.

METHODS

Study design and patient selection

We used data from consecutive patients with acute ischemic stroke due to anterior circulation LVO from the Multicentre Randomised Controlled Trial of Endovascular Treatment for Acute Ischaemic Stroke in The Netherlands (MR CLEAN) Registry, a prospective, observational cohort study for stroke intervention centers that perform EVT in The Netherlands.¹⁴ All 18 centers performing EVT in The Netherlands participated in this registry. Enrollment started in March 2014, directly after the final randomization for the MR CLEAN trial, and ended in December 2018.¹⁵ We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.¹⁶

For the present study, we used data from all patients in the registry who fulfilled the following criteria: aged ≥ 18 years, treatment in a center that had participated in the MR CLEAN trial, start of EVT within 6.5 hours of symptom onset, and occlusion of the intracranial carotid artery, middle cerebral artery segment (M1/M2), or anterior cerebral artery segment (A1/A2), as confirmed on CT angiography. In addition, a non-contrast CT scan was performed on admission to rule out intracranial hemorrhage.

Table 2 Workflow metrics

Workflow times and treatment	Women (n=2320)	Men (n=2552)	Unadjusted OR/ difference (95% CI)	Adjusted OR/ difference (95% CI)
Onset-to-door time*§	2 hours 16 min (1 hour 27 min)	2 hours 7 min (1 hour 30 min)	10 min (5 to 15)	9 min (4 to 13)
Stratified by interhospital transfer				
Yes	3 hours 1 min (1 hour 9 min)	2 hours 53 min (1 hour 9 min)	7 min (2 to 13)	9 min (3 to 15)
No	1 hour 23 min (1 hour 17 min)	1 hour 15 min (1 hour 23 min)	9 min (2 to 15)	8 min (1 to 15)
Door-to-groin time†§	1 hour 4 min (43 min)	1 hour 3 min (41 min)	1 min (–2 to 3)	2 min (0 to 4)
Onset-to-groin time‡§	3 hours 26 min (1 hour 16 min)	3 hours 13 min (1 hour 13 min)	13 min (9 to 17)	13 min (9 to 17)
Interhospital transfer (n/total No (%))¶	1277/2319 (55.1)	1371/2550 (53.8)	1.05 (0.94 to 1.18)	1.07 (0.95 to 1.21)
IVT treatment (n/total No (%))**	1668/2305 (72.4)	1877/2541 (73.9)	0.93 (0.82 to 1.05)	1.05 (0.89 to 1.23)

Workflow variables are mean (SD), unless otherwise stated.
*Number of missing values: 89 (3.8%) and 96 (3.8%) in women and men, respectively.
†Number of missing values: 228 (9.8%) and 248 (9.7%) in women and men, respectively.
‡Number of missing values: 42 (1.8%) and 48 (1.9%) in women and men, respectively.
§Adjusted for age, National Institutes of Health Stroke Scale (NIHSS) at baseline, hypertension, prestroke modified Rankin Scale (mRS), interhospital transfer, treatment with IVT, use of general anesthesia, and admission outside office hours.
¶Adjusted for age, NIHSS at baseline, history of ischemic stroke, and prestroke mRS.
**Adjusted for age, hypertension, NIHSS at baseline, prestroke mRS, anticoagulants, history of ischemic or hemorrhagic stroke, admission outside office hours, and onset-to-door time.
EVT, endovascular treatment; IVT, intravenous thrombolysis.

Although the recommended time window for EVT at the time of this study was 6 hours,¹⁷ the time window was extended by 30 min compared with that in the MR CLEAN trial because the start of groin puncture was sometimes slightly delayed due to logistical reasons in clinical practice. EVT consisted of arterial catheterization followed by mechanical thrombectomy and thrombus aspiration, with or without delivery of a thrombolytic agent.

Clinical baseline characteristics were collected as previously described and included sex, age, blood pressure on admission, vascular risk factors, vascular comorbidity, medication use, and stroke etiology, classified according to the Trial of ORG 10172 in Acute Stroke Treatment criteria.^{14 18}

Outcome measures

The main prehospital workflow related metric of interest was time from stroke onset to arrival at the emergency department of the intervention center (onset-to-door time) as a measure of prehospital delay. In addition, we assessed time from admission to the emergency department of the intervention center to groin puncture (door-to-groin time) as a measure for inhospital delay, time from stroke onset to groin puncture (onset-to-groin time), proportion of patients treated with intravenous thrombolytics (IVT), and proportion of patients with an interhospital transfer.

Admission and discharge functional status were based on the modified Rankin Scale (mRS). This is a 7 point scale ranging from 0 (no symptoms) to 6 (death).¹⁹ Prestroke disability was defined as an mRS score of ≥ 1 , and was evaluated and recorded at admission by the treating clinician.¹⁵ Good neurological outcome at 90 days was defined as an mRS ≤ 2 .¹⁴

Clinical symptoms and stroke severity were assessed according to the National Institutes of Health Stroke Scale (NIHSS) on admission. Stroke severity was dichotomized as NIHSS score < 10 (mild to moderately severe stroke) and ≥ 10 (moderate to severe stroke).²⁰ The following symptoms were recorded from the NIHSS: change in level of consciousness, loss of consciousness/coma, gaze deviation, visual field deficit, facial weakness, motor deficit in the arm or leg, ataxia, numbness, aphasia, dysarthria, and neglect. Categories differentiating the left and right side in arm and leg motor function were merged.

Statistical analysis

We compared baseline characteristics between men and women using the t test or Mann–Whitney U test for continuous variables and the Pearson's χ^2 test for categorical variables. We used multivariable linear regression analysis to study the association between sex and workflow times and calculated adjusted β coefficients. For the remaining end points, we used multivariable binary logistic regression analyses and calculated the adjusted OR (aOR). All regression analyses were adjusted for relevant confounders based on previous literature and the expert opinion of two vascular neurologists.

For the regression analyses with prehospital and in-hospital workflow times as outcomes, we adjusted for the following factors: age, NIHSS at baseline, hypertension (baseline systolic blood pressure > 185 mm Hg and diastolic blood pressure > 110 mm Hg), prestroke mRS, interhospital transfer, treatment with IVT, use of general anesthesia, and admission outside office hours. In addition, we analyzed onset-to-door time stratified by interhospital transfer, adjusting for all previous variables.

For the regression analysis with IVT treatment as an outcome, we adjusted for age, hypertension (baseline systolic blood pressure > 185 mm Hg and diastolic blood pressure > 110 mm Hg), NIHSS at baseline, prestroke mRS, anticoagulants, history of ischemic or hemorrhagic stroke, admission outside office hours, and onset-to-door time. The regression analysis for interhospital transfer was adjusted for age, NIHSS at baseline, history of ischemic stroke, and prestroke mRS.

The regression analysis for prestroke mRS score (dichotomized, with mRS score of ≥ 1 as prestroke disability) was adjusted for age, vascular risk factors, comorbidities, and medication use, as described in table 1. For mRS score at 90 days after stroke (dichotomized, with mRS score of 0–2 as good functional outcome), we adjusted for age, NIHSS at baseline, prestroke mRS, prior stroke, systolic blood pressure, peripheral artery disease, treatment with IVT, collateral score, and onset-to-groin time.

The regression analysis for stroke severity (using NIHSS in two categories) was adjusted for the same variables as for the analysis of prestroke mRS score, as well as for the variable prestroke mRS. For the regression analysis on clinical symptoms, adjustments were made for age, comorbidities as described in table 1,

Ischemic stroke




Figure 1 Distribution of modified Rankin Scale (mRS) scores before stroke (A) and 3 months after stroke (B).

and prestroke mRS. We constructed forest plots to display the effect estimates for NIHSS scores and per symptom.

For all analyses, complete case analysis was performed because we expected that data were missing not at random. A p value <0.05 was considered significant. SPSS V.25.0 (IBM Corp, Armonk, New York, USA) was used for the statistical analyses.

RESULTS

Of 5768 patients registered during the study period, 4872 were included in the current analysis: 2320 (47.6%) were women (online supplemental figure I). Compared with men, women were older at stroke onset (median age 76 vs 70 years) and were more likely to have a history of hypertension and atrial fibrillation, but were less likely to have a history of myocardial infarction or current smoking. Cardioembolic stroke was more common in women whereas large artery atherosclerosis stroke and stroke of other determined cause were less common. Other baseline characteristics are shown in table 1. Women less often achieved good functional outcome at 90 days compared with

men (mRS ≤2: 35.2% vs 46.4%, aOR 0.70, 95% CI 0.60 to 0.82).

Workflow metrics

Mean onset-to-door time was longer for women compared with men (2 hours 16 min vs 2 hours 7 min, adjusted delay 9 min, 95% CI 4 to 13). This result was unchanged following stratification for interhospital transfer (table 2). Mean door-to-groin time was similar in men and women (1 hour 4 min vs 1 hour 3 min, adjusted delay 2 min, 95% CI 0 to 4). Onset-to-groin time (3 hours 26 min vs 3 hours 13 min, adjusted delay 13 min, 95% CI 9 to 17) was longer for women than men. We found no differences in the proportion of men and women treated with IVT or with interhospital transfer (table 2).

Prestroke disability

Women more often had prestroke disability compared with men (mRS ≥1: 41.1% vs 29.1%, aOR 1.57, 95% CI 1.36 to 1.82). The distribution of prestroke mRS scores is shown in figure 1.

Clinical symptoms and stroke severity

Figure 2 shows a forest plot for stroke severity and clinical symptoms. Men and women had comparable NIHSS scores at baseline (mean 15 ± 6 vs 15 ± 6, NIHSS <10 vs ≥10, aOR 0.91, 95% CI 0.78 to 1.06). There were no significant sex differences in the occurrence of specific clinical symptoms on admission except that women less frequently had visual field deficits compared with men (52.1% vs 55.3%, aOR 0.83, 95% CI 0.74 to 0.94).

DISCUSSION

We found that women with anterior circulation LVO, who were treated with EVT, had longer onset-to-door times. Also, women more often had prestroke disability and less often achieved good functional outcome than men. Onset-to-groin times were significantly longer, which seemed to be mainly caused by later arrival because in-hospital workflow times were similar. Clinical symptoms on admission were similar except for a small difference in the occurrence of visual field deficits.

Our study specifically focused on contributors to poor outcomes in the prehospital phase in the real world setting. This is different from most previous studies, making direct comparisons for several outcomes difficult. Furthermore, substantial variability in the design, inclusion criteria, and adjustment for




Figure 2 Clinical symptoms and stroke severity recorded from the NIHSS score on admission. *Dichotomized at <10 and ≥10.²⁰ †Number of missing values: 33 (1.4%) and 36 (1.4%) in men and women, respectively. aOR, adjusted OR; NIHSS, National Institutes of Stroke Scale.

confounders hampers comparisons across studies. Although data for the role of sex in outcome after EVT are scarce and conflicting, multiple articles have been published recently pointing out these disparities. However, these studies had a smaller sample size and, most importantly, did not correct their analyses for potential confounders, decreasing the reliability of their results. Also, in contrast with most EVT studies highlighting sex specific aspects of inhospital management, our study specifically focused on sex differences in the prehospital phase and recommends to assess why women have later hospital arrival.

We found four studies that reported similar time metrics in terms of onset-to-door times, door-to-groin times, and onset-to-groin times between men and women with LVO.^{4 7 21 22} However, these studies either had a small sample size or their analysis was not adjusted for potential confounders that might affect prehospital and in-hospital workflow times.

Similar to the findings in previous studies on stroke in general, we showed that women more often have prestroke disability.^{9 23 24} In our population, women were older than men, more often had hypertension, and had a higher prevalence of atrial fibrillation. These characteristics have been associated with a worse prestroke functional status and higher stroke severity,²⁵ although in our study men and women had similar NIHSS on admission.

In contrast with previous studies on ischemic stroke in general, we did not find sex differences in the use of IVT.^{26–28} Less frequent use of IVT in women compared with men was first documented in a previous meta-analysis of 18 studies published between 2000 and 2008 (pooled OR 0.70, 95% CI 0.55 to 0.88).¹¹ The odds of treatment were still lower for women in an updated systematic review and meta-analysis of 17 studies published between 2008 and 2018, but more recent data suggest that the magnitude of this sex difference decreased (pooled OR 0.87, 95% CI 0.82 to 0.93).²⁹ In the MR CLEAN Registry, only patients with LVO were included in whom the neurological deficits are typically severe. This most likely explains why we found no sex differences in treatment with IVT. Moreover, in our study, sex differences were not observed among interhospital transfers. Similar results with respect to interhospital transfers were reported by three previous studies assessing sex differences in outcome after EVT.^{4 23 30} However, these studies did not adjust for confounders that might affect interhospital transfer (eg, age and NIHSS score at baseline).

The major strength of the study was our large, well described population of almost 5000 patients recruited from a nationwide prospective registry. This registry included consecutive patients from all intervention centers in The Netherlands and, therefore, our results likely reflect daily clinical practice. Moreover, the distribution of men and women included in our study was equal.

Our study had some limitations. First, only data for patients who received EVT are recorded in the MR CLEAN Registry. Therefore, we had no information on patients who did not receive EVT due to, for example, late arrival or because they did not have a suspicion of stroke. Because women with ischemic stroke have a higher prevalence of non-focal stroke symptoms compared with men, we cannot exclude the fact that female ischemic stroke patients with LVO were missed more.¹³ Therefore, we cannot estimate the size of this patient population and their impact on our results. In particular, this selection could possibly explain why we did not observe significant sex differences regarding clinical symptoms. Another limitation of our study was that we had no information on prehospital delay to distinguish between delays in calling emergency medical services and the use of transportation modes (as measures of patient delay) and delay because of inhospital workflow in the primary

stroke center and interhospital transfer (as measures of system delay). This information might have provided more insight into the various elements of prehospital workflow. Furthermore, information about living status was lacking (eg, living alone vs living with family or carers). Because older patients may be more likely to live alone and present later after a stroke compared with younger patients, selection bias towards the exclusion of older women who more frequently live alone has possibly occurred.^{9 11} Future investigation of living status could provide additional insights about sex differences in onset-to-door times. Lastly, even though we adjusted our analyses for known confounding factors, we cannot exclude the presence of residual confounding.

Our study indicates that onset-to-door times are prolonged in women with anterior circulation LVO. More detailed studies of specific processes of prehospital workflow are necessary to understand the origin of the sex disparity in hospital arrival times. Stroke education/awareness campaigns targeted at women have focused only on stroke prevention through monitoring of vascular risk factors and disparities in stroke symptoms. Importantly, the American Heart Association's Go Red for Women campaign on stroke symptoms did not specifically focus on the need for fast activation of emergency medical services after onset of stroke symptoms. As a result of poorer health education, women may be less aware of the emergency nature of the disease. Based on our results, we suggest that campaigns should focus on both the recognition of stroke symptoms and activation of emergency medical services to reduce delays in seeking .

CONCLUSION

Our study indicates important sex differences in onset-to-door times and prestroke disability in patients with anterior circulation LVO, but no substantial differences between men and women in terms of clinical symptoms. These sex differences may contribute to differences in outcome after EVT. Additional research of underlying causes of sex differences in arrival times is needed to establish equitable access to treatment and improve outcome in women with LVO.

Author affiliations

- ¹Neurology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
- ²Neurology, Leiden University Medical Center, Leiden, The Netherlands
- ³Surgery, Amsterdam UMC, Location VUmc, Amsterdam, Netherlands
- ⁴Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands
- ⁵Neurology, Zaans Medical Center, Zaandam, The Netherlands
- ⁶Neurology, Rijnstate Hospital, Arnhem, The Netherlands
- ⁷University of Twente Faculty of Science and Technology, Enschede, The Netherlands
- ⁸Neurology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands
- ⁹Neurology, HMC Westeinde, The Hague, The Netherlands
- ¹⁰Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands
- ¹¹Radiology and Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands
- ¹²Neurology, Sint Antonius Hospital, Nieuwegein, The Netherlands
- ¹³Radiology, Leiden University Medical Center, Leiden, The Netherlands
- ¹⁴Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

Twitter Ido R van den Wijngaard @Strokologist

Acknowledgements We thank the Multicentre Randomised Controlled Trial of Endovascular Treatment for Acute Ischaemic Stroke in The Netherlands (MR CLEAN) Registry investigators (see online supplemental material).

Collaborators MR CLEAN Registry Investigators – group authors Executive committee Diederik W.J. Dippel¹; Aad van der Lugt²; Charles B.L.M. Majoie³; Yvo B.W.E.M. Roos⁴; Robert J. van Oostenbrugge^{5,44}; Wim H. van Zwam^{6,44}; Jelis Boiten¹⁴; Jan Albert Vos⁸. Study coordinators Ivo G.H. Jansen³; Maxim J.H.L. Mulder^{1,2}; Robert-Jan B. Goldhoorn^{5,6,44}; Kars C.J. Compagne²; Manon Kappelhof³; Josje Brouwer⁴; Sanne J. den Hartog^{1,2,40}; Wouter H. Hinsenveld^{5,6}; Lotte van den Heuvel^{1,40}. Local principal investigators Diederik W.J. Dippel¹; Bob Roozenbeek¹;

Aad van der Lugt²; Pieter Jan van Doormaal²; Charles B.L.M. Majoie³; Yvo B.W.E.M. Roos⁴; Bart J. Emmer³; Jonathan M. Coutinho⁴; Wouter J. Schonewille⁷; Jan Albert Vos⁸; Marieke J.H. Wermer⁹; Marianne A.A. van Walderveen¹⁰; Adriaan C.G.M. van Es¹⁰; Julie Staals^{5,44}; Robert J. van Oostenbrugge^{5,44}; Wim H. van Zwam^{6,44}; Jeannette Hofmeijer¹¹; Jasper M. Martens¹²; Geert J. Lycklama à Nijeholt¹³; Jelis Boiten¹⁴; Sebastiaan F. de Bruijn¹⁵; Lukas C. van Dijk¹⁶; H. Bart van der Worp¹⁷; Rob H. Lo¹⁸; Ewoud J. van Dijk¹⁹; Hieronymus D. Boogaarts²⁰; J. de Vries²²; Paul L.M. de Kort²¹; Julia van Tuijl²¹; Issam Boukrab²⁶; Jo P. Peluso²⁶; Puck Franssen²²; Jan S.P. van den Berg²²; Heleen M. den Hertog²²; Boudewijn A.A.M. van Hasselt²³; Leo A.M. Aerden²⁴; René J. Dallinga²⁵; Maarten Uyttenboogaart²⁸; Omid Eschgi²⁹; Reinoud P.H. Bokkers²⁹; Tobien H.C.M.L. Schreuder³⁰; Roel J.J. Heijboer³¹; Koos Keizer³²; Rob A.R. Gons³²; Lonke S.F. Yo³³; Emiel J.C. Sturm^{35,47}; Tomas Bulut³⁵; Paul J.A.M. Brouwers³⁴; Anouk D. Rozeman⁴²; Otto Elgersma⁴¹; Michel J.M. Remmers⁴³; Thijs E.A.M. de Jong⁴⁶. **Imaging assessment committee** Charles B.L.M. Majoie³(chair); Wim H. van Zwam^{6,44}; Aad van der Lugt²; Geert J. Lycklama à Nijeholt¹³; Marianne A.A. van Walderveen¹⁰; Marieke E.S. Sprengers³; Sjoerd F.M. Jenniskens²⁷; René van den Berg³; Albert J. Yoo³⁸; Ludo F.M. Beenen³; Alida A. Postma^{6,45}; Stefan D. Roosendaal³; Bas F.W. van der Kallen¹³; Ido R. van den Wijngaard¹³; Adriaan C.G.M. van Es¹⁰; Bart J. Emmer³; Jasper M. Martens¹²; Lonke S.F. Yo³³; Jan Albert Vos⁸; Joost Bot³⁶; Pieter-Jan van Doormaal²; Anton Meijer²⁷; Elyas Ghariq¹³; Reinoud P.H. Bokkers²⁹; Marc P. van Proosdij³⁷; G. Menno Krietemeijer³³; Jo P. Peluso²⁶; Hieronymus D. Boogaarts²⁰; Rob Lo¹⁸; Wouter Dinkelaar⁴¹; Auke P.A. Appelman²⁹; Bas Hammer¹⁶; Sjoert Pegge²⁷; Anouk van der Hoorn²⁹; Saman Vinke²⁰; Sandra Cornelissen²; Christiaan van der Leij⁶; Rutger Brans⁶; Jeanette Bakker⁴¹; Maarten Uyttenboogaart²⁸; Miou Koopman³; Lucas Smagge²; Olvert A. Berkhemer^{1,3,6}; Jeroen Markensteijn³; Eef Hendriks³; Patrick Brouwer¹⁰; Dick Gerrits³⁵. **Writing committee** Diederik W.J. Dippel¹(chair); Aad van der Lugt²; Charles B.L.M. Majoie³; Yvo B.W.E.M. Roos⁴; Robert J. van Oostenbrugge^{5,44}; Wim H. van Zwam^{6,44}; Geert J. Lycklama à Nijeholt¹³; Jelis Boiten¹⁴; Jan Albert Vos⁸; Wouter J. Schonewille⁷; Jeannette Hofmeijer¹¹; Jasper M. Martens¹²; H. Bart van der Worp¹⁷; Rob H. Lo¹⁸. **Adverse event committee** Robert J. van Oostenbrugge^{5,44}(chair); Jeannette Hofmeijer¹¹; H. Zwenneke Flach²³. **Trial methodologist** Hester F. Lingsma⁴⁰. **Research nurses / local trial coordinators** Naziha el Ghannouti¹; Martin Sterrenberg¹; Wilma Pelikaan⁷; Rita Sprengers⁴; Marjan Elfrink¹¹; Michelle Simons¹¹; Marjolein Vossers¹²; Joke de Meris¹⁴; Tamara Vermeulen¹⁴; Annet Geerlings¹⁹; Gina van Vemde²²; Tiny Simons³⁰; Gert Messchendorp²⁸; Nynke Nicolaij²⁸; Hester Bongenaar³²; Karin Bodde²⁴; Sandra Kleijn³⁴; Jasmijn Lodico³⁴; Hanneke Droste³⁴; Maureen Wollaert³; Sabrina Verheesen⁵; D. Jeurissen⁵; Erna Bos⁹; Yvonne Drabbe¹⁵; Michelle Sandiman¹⁵; Nicoline Aaldering¹¹; Berber Zweedijk¹⁷; Jovoca Vervoort²¹; Eva Ponjee²²; Sharon Romviel¹⁹; Karin Kanselaar¹⁹; Denn Barning¹; Laurine van der Steen³. **Clinical/imaging data acquisition** Esme Venema⁴⁰; Vicky Chalos^{1,40}; Ralph R. Geuskens³; Tim van Straaten¹⁹; Saliha Ergezen¹; Roger R.M. Harmsma¹; Daan Muijres¹; Anouk de Jong¹; Olvert A. Berkhemer^{1,3,6}; Anna M.M. Boers^{3,39}; J. Huguet³; P.F.C. Groot³; Marieke A. Mens³; Katinka R. van Kranendonk³; Kilian M. Treurniet³; Manon L. Tolhuisen^{3,39}; Heitor Alves³; Annick J. Weterings³; Eleonora L.F. Kirkels³; Eva J.H.F. Voogd¹¹; Lieve M. Schupp³; Sabine L. Collette^{28,29}; Adrien E.D. Groot⁴; Natalie E. LeCouffe⁴; Praneeta R. Konduri³⁹; Haryadi Prasetya³⁹; Nerea Arrarte-Terreros³⁹; Lucas A. Ramos³⁹; Nikki Boodt^{1,2,40}; Anne F.A.V. Pirson⁵; Agnetha A.E. Bruggeman³; Nadinda A.M. van der Ende^{1,2}; Rabia Deniz³; Susanne G.H. Olthuis^{5,44}; Floor Pinckaers^{6,44}. **List of affiliations** Department of Neurology¹, Radiology², Public Health⁴⁰, Erasmus MC University Medical Center; Department of Radiology and Nuclear Medicine³, Neurology⁴, Biomedical Engineering & Physics³⁹, Amsterdam UMC, location University of Amsterdam; Department of Neurology⁵, Radiology & Nuclear Medicine⁶, Maastricht University Medical Center+; School for Cardiovascular Diseases Maastricht (CARIM)⁴⁴ and MHeNs School for Mental Health and Neuroscience, Maastricht, the Netherlands⁴⁵; Department of Neurology⁷, Radiology⁸, Sint Antonius Hospital, Nieuwegein; Department of Neurology⁹, Radiology¹⁰, Leiden University Medical Center; Department of Neurology¹¹, Radiology¹², Rijnstate Hospital, Arnhem; Department of Radiology¹³, Neurology¹⁴, Haaglanden MC, the Hague; Department of Neurology¹⁵, Radiology¹⁶, Haga Hospital, the Hague; Department of Neurology¹⁷, Radiology¹⁸, University Medical Center Utrecht; Department of Neurology¹⁹, Neurosurgery²⁰, Radiology²⁷, Radboud University Medical Center, Nijmegen; Department of Neurology²¹, Radiology²⁶, Elisabeth-TweeSteden ziekenhuis, Tilburg; Department of Neurology²², Radiology²³, Isala Klinieken, Zwolle; Department of Neurology²⁴, Radiology²⁵, Reinier de Graaf Gasthuis, Delft; Department of Neurology²⁸, Radiology²⁹, University Medical Center Groningen; Department of Neurology³⁰, Radiology³¹, Atrium Medical Center, Heerlen; Department of Neurology³², Radiology³³, Catharina Hospital, Eindhoven; Department of Neurology³⁴, Radiology³⁵, Medisch Spectrum Twente, Enschede, (currently Deventer Hospital⁴⁷); Department of Radiology³⁶, Amsterdam UMC, Vrije Universiteit van

Amsterdam, Amsterdam; Department of Radiology³⁷, Noordwest Ziekenhuisgroep, Alkmaar; Department of Radiology³⁸, Texas Stroke Institute, Texas, United States; Department of Neurology⁴², Radiology⁴¹, Albert Schweitzer Hospital, Dordrecht; Department of Neurology⁴³, Radiology⁴⁶, Amphia Hospital, Breda.

Contributors MarA and MJHW: conception and design of the study, and drafting of the manuscript. MarA, AvdM, HJAvO, and MahA: data and statistical analysis. EWvZ: supervision of statistical analysis. AvdM, JH, WJS, MAAvW, IRvdW, and ACGMvE: acquisition of clinical data. CBLMM and DWJD: members of the trial executive committee and critical review and revision. FHMS, PJN, MCV, and NDK: critical review and revision for valuable intellectual content. MarA is guarantor of the data.

Funding The Multicentre Randomised Controlled Trial of Endovascular Treatment for Acute Ischaemic Stroke in The Netherlands (MR CLEAN) Registry was partly funded by the TWIN Foundation, Erasmus MC University Medical Centre, Amsterdam University Medical Centre, and Maastricht University Medical Centre.

Competing interests MJHW reports funding from the Dutch Research Council (VIDI grant 91717337). CBLMM reports funding from the TWIN Foundation, CVON/Dutch Heart Foundation, European Commission, Health Evaluation Netherlands, and Stryker, all outside the submitted work (paid to institution); he is shareholder of Nicolab. DWJD reports funding from the Dutch Heart Foundation, Brain Foundation Netherlands, The Netherlands Organisation for Health Research and Development, Health Holland Top Sector Life Sciences and Health, and unrestricted grants from Penumbra Inc, Stryker European Operations BV, Medtronic, Thrombolytic Science, and Cerenovus, all paid to institution. JH reports funding from the Dutch Heart Foundation, Brain Foundation Netherlands, and ZonMw, all paid to institution. IRvdW reports funding from Jacobus Stichting. PJN reports funding from the Dutch Heart Foundation and The Netherlands Organisation for Health Research and Development, both paid to institution.

Patient consent for publication Not applicable.

Ethics approval The central medical ethics committee of the Erasmus Medical Centre Rotterdam, The Netherlands, granted permission to perform the study as a registry (MEC-2014-235). They waived the need for obtaining written informed consent, but patients or their representatives were informed about the study orally and in writing.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. Data cannot be made available to other researchers, as no patient approval has been obtained for sharing coded data. However, syntax and output files of statistical analyses are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs

Mariam Ali <http://orcid.org/0000-0003-3409-7835>
 Mahsoem Ali <http://orcid.org/0000-0002-0511-6323>
 Charles B L M Majoie <http://orcid.org/0000-0002-7600-9568>
 Wouter J Schonewille <http://orcid.org/0000-0002-4070-9730>
 Diederik W J Dippel <http://orcid.org/0000-0002-9234-3515>

REFERENCES

- Madsen TE, DeCroce-Movson E, Hemendinger M, *et al.* Sex differences in 90-day outcomes after mechanical thrombectomy for acute ischemic stroke. *J Neurointerv Surg* 2019;11:221–5.
- Uchida K, Yoshimura S, Sakai N, *et al.* Sex differences in management and outcomes of acute ischemic stroke with large vessel occlusion. *Stroke* 2019;50:1915–8.
- Dmytriw AA, Ku JC, Yang VXD, *et al.* Do outcomes between women and men differ after endovascular thrombectomy? A meta-analysis. *AJNR Am J Neuroradiol* 2021;42:910–5.
- Fifi JT, Nguyen TN, Song S, *et al.* Sex differences in endovascular thrombectomy outcomes in large vessel occlusion: a propensity-matched analysis from the SELECT study. *J Neurointerv Surg* 2023;15:105–12.
- Chalos V, de Ridder IR, Lingsma HF, *et al.* Does sex modify the effect of endovascular treatment for ischemic stroke? *Stroke* 2019;50:2413–9.
- Lagebrant C, Ramgren B, Hassani Espili A, *et al.* Sex differences in collateral circulation and outcome after mechanical thrombectomy in acute ischemic stroke. *Front Neurol* 2022;13:878759.

- 7 Sheth SA, Lee S, Warach SJ, *et al.* Sex differences in outcome after endovascular stroke therapy for acute ischemic stroke. *Stroke* 2019;50:2420–7.
- 8 Ospel JM, Schaafsma JD, Leslie-Mazwi TM, *et al.* Toward a better understanding of sex- and gender-related differences in endovascular stroke treatment: a scientific statement from the American Heart Association/American Stroke Association. *Stroke* 2022;53.
- 9 Di Carlo A, Lamassa M, Baldereschi M, *et al.* Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. *Stroke* 2003;34:1114–9.
- 10 Gattringer T, Ferrari J, Knoflach M, *et al.* Sex-related differences of acute stroke unit care: results from the Austrian stroke unit registry. *Stroke* 2014;45:1632–8.
- 11 Reeves MJ, Prager M, Fang J, *et al.* Impact of living alone on the care and outcomes of patients with acute stroke. *Stroke* 2014;45:3083–5.
- 12 Bushnell C, Howard VJ, Lisabeth L, *et al.* Sex differences in the evaluation and treatment of acute ischaemic stroke. *Lancet Neurol* 2018;17:641–50.
- 13 Ali M, van Os HJA, van der Weerd N. Sex differences in presentation of stroke: a systematic review and meta-analysis. *Stroke* 2021.
- 14 Jansen IGH, Mulder MJHL, Goldhoorn R-JB, *et al.* Endovascular treatment for acute ischaemic stroke in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry). *BMJ* 2018;360:k949.
- 15 Berkhemer OA, Fransen PSS, Beumer D, *et al.* A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med* 2015;372:11–20.
- 16 von Elm E, Altman DG, Egger M, *et al.* The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370:1453–7.
- 17 Powers WJ, Rabinstein AA, Ackerson T, *et al.* 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2018;49:e46–110.
- 18 Adams HP, Bendixen BH, Kappelle LJ, *et al.* Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993;24:35–41.
- 19 van Swieten JC, Koudstaal PJ, Visser MC, *et al.* Interobserver agreement for the assessment of handicap in stroke patients. *Stroke* 1988;19:604–7.
- 20 Langezaal LCM, van der Hoeven EJRJ, Mont'Alverne FJA, *et al.* Endovascular therapy for stroke due to basilar-artery occlusion. *N Engl J Med* 2021;384:1910–20.
- 21 Casetta I, Fainardi E, Pracucci G, *et al.* Sex differences in outcome after thrombectomy for acute ischemic stroke. A propensity score-matched study. *Eur Stroke J* 2022;7:151–7.
- 22 Momen AI, Francis T, Schaafsma JD, *et al.* Sex differences in functional outcomes following EVT for acute ischemic stroke. *Can J Neurol Sci* 2022:1–22.
- 23 Deb-Chatterji M, Schlemm E, Flottmann F, *et al.* Sex differences in outcome after thrombectomy for acute ischemic stroke are explained by confounding factors. *Clin Neuroradiol* 2021;31:1101–9.
- 24 Renoux C, Coulombe J, Li L, *et al.* Confounding by pre-morbid functional status in studies of apparent sex differences in severity and outcome of stroke. *Stroke* 2017;48:2731–8.
- 25 Kelly-Hayes M, Beiser A, Kase CS, *et al.* The influence of gender and age on disability following ischemic stroke: the Framingham study. *J Stroke Cerebrovasc Dis* 2003;12:119–26.
- 26 Asdaghi N, Romano JG, Wang K, *et al.* Sex disparities in ischemic stroke care: FL-PR CReSD study (Florida-Puerto Rico collaboration to reduce stroke disparities). *Stroke* 2016;47:2618–26.
- 27 Faigle R, Urrutia VC, Cooper LA, *et al.* Individual and system contributions to race and sex disparities in thrombolysis use for stroke patients in the United States. *Stroke* 2017;48:990–7.
- 28 Towfighi A, Markovic D, Ovbiagele B. Sex differences in revascularization interventions after acute ischemic stroke. *J Stroke Cerebrovasc Dis* 2013;22:e347–53.
- 29 Strong B, Lisabeth LD, Reeves M. Sex differences in IV thrombolysis treatment for acute ischemic stroke: a systematic review and meta-analysis. *Neurology* 2020;95:e11–22.
- 30 Zerna C, Rogers E, Rabi DM, *et al.* Sex differences in endovascular treatment for stroke: a population-based analysis. *Can J Neurol Sci* 2021;48:479–86.